Mizuho reaffirmed their buy rating on shares of Nightstar Therapeutics (NASDAQ:NITE) in a research report released on Thursday morning. They currently have a $20.00 target price on the stock.
“We are less concerned about financial performance than progress in the pipeline. In our view, Nightstar has the most comprehensive data in Choroideremia (CHM) in the gene therapy space. The phase 3 STAR trial of NSR-REP1 in CHM was recently initiated and could be adequate to support a BLA filing in 2020.”,” Mizuho’s analyst commented.
NITE has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $31.00 price objective on shares of Nightstar Therapeutics in a research report on Wednesday, March 7th. Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a research report on Wednesday, January 3rd. They set a buy rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $28.50.
NITE stock opened at $11.70 on Thursday. Nightstar Therapeutics has a one year low of $10.01 and a one year high of $24.93. The firm has a market cap of $328.77 and a price-to-earnings ratio of -7.18.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC acquired a new stake in shares of Nightstar Therapeutics during the fourth quarter worth $1,771,000. Alyeska Investment Group L.P. acquired a new stake in shares of Nightstar Therapeutics during the third quarter worth $1,920,000. Citadel Advisors LLC acquired a new stake in shares of Nightstar Therapeutics during the third quarter worth $240,000. Ameriprise Financial Inc. acquired a new stake in shares of Nightstar Therapeutics during the third quarter worth $5,761,000. Finally, Nationwide Fund Advisors acquired a new stake in shares of Nightstar Therapeutics during the third quarter worth $1,196,000. 29.06% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Nightstar Therapeutics (NITE) Earns Buy Rating from Mizuho” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/08/nightstar-therapeutics-nite-earns-buy-rating-from-mizuho.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.